These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

782 related items for PubMed ID: 19523672

  • 1. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract.
    Amar SM, Harbeck RJ, Sills M, Silveira LJ, O'Brien H, Nelson HS.
    J Allergy Clin Immunol; 2009 Jul; 124(1):150-156.e1-5. PubMed ID: 19523672
    [Abstract] [Full Text] [Related]

  • 2. Clinical efficacy of microencapsulated timothy grass pollen extract in grass-allergic individuals.
    TePas EC, Hoyte EG, McIntire JJ, Umetsu DT.
    Ann Allergy Asthma Immunol; 2004 Jan; 92(1):25-31. PubMed ID: 14756461
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy.
    Rossi RE, Monasterolo G, Coco G, Silvestro L, Operti D.
    Vaccine; 2007 Jan 15; 25(5):957-64. PubMed ID: 17045368
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study.
    Bufe A, Ziegler-Kirbach E, Stoeckmann E, Heidemann P, Gehlhar K, Holland-Letz T, Braun W.
    Allergy; 2004 May 15; 59(5):498-504. PubMed ID: 15080830
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of high-doses sublingual immunotherapy in ultra-rush scheme in children allergic to grass pollen.
    Stelmach I, Kaczmarek-Woźniak J, Majak P, Olszowiec-Chlebna M, Jerzynska J.
    Clin Exp Allergy; 2009 Mar 15; 39(3):401-8. PubMed ID: 19134016
    [Abstract] [Full Text] [Related]

  • 6. Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually.
    Panzner P, Petrás M, Sýkora T, Lesná I.
    Respir Med; 2008 Sep 15; 102(9):1296-304. PubMed ID: 18585908
    [Abstract] [Full Text] [Related]

  • 7. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
    Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S.
    J Allergy Clin Immunol; 2006 Apr 15; 117(4):802-9. PubMed ID: 16630937
    [Abstract] [Full Text] [Related]

  • 8. Dose dependence of immunological response to sublingual immunotherapy.
    Marcucci F, Sensi L, Di Cara G, Incorvaia C, Frati F.
    Allergy; 2005 Jul 15; 60(7):952-6. PubMed ID: 15932387
    [Abstract] [Full Text] [Related]

  • 9. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen.
    Skoner D, Gentile D, Bush R, Fasano MB, McLaughlin A, Esch RE.
    J Allergy Clin Immunol; 2010 Mar 15; 125(3):660-6, 666.e1-666.e4. PubMed ID: 20153030
    [Abstract] [Full Text] [Related]

  • 10. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen.
    Rolinck-Werninghaus C, Wolf H, Liebke C, Baars JC, Lange J, Kopp MV, Hammermann J, Leupold W, Bartels P, Gruebl A, Bauer CP, Schnitker J, Wahn U, Niggemann B.
    Allergy; 2004 Dec 15; 59(12):1285-93. PubMed ID: 15507097
    [Abstract] [Full Text] [Related]

  • 11. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.
    Valovirta E, Jacobsen L, Ljørring C, Koivikko A, Savolainen J.
    Allergy; 2006 Oct 15; 61(10):1177-83. PubMed ID: 16942565
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study.
    Ott H, Sieber J, Brehler R, Fölster-Holst R, Kapp A, Klimek L, Pfaar O, Merk H.
    Allergy; 2009 Jan 15; 64(1):179-86. PubMed ID: 19076534
    [Abstract] [Full Text] [Related]

  • 13. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
    Didier A, Worm M, Horak F, Sussman G, de Beaumont O, Le Gall M, Melac M, Malling HJ.
    J Allergy Clin Immunol; 2011 Sep 15; 128(3):559-66. PubMed ID: 21802126
    [Abstract] [Full Text] [Related]

  • 14. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE.
    Cox LS, Casale TB, Nayak AS, Bernstein DI, Creticos PS, Ambroisine L, Melac M, Zeldin RK.
    J Allergy Clin Immunol; 2012 Dec 15; 130(6):1327-34.e1. PubMed ID: 23122534
    [Abstract] [Full Text] [Related]

  • 15. Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis.
    Smith H, White P, Annila I, Poole J, Andre C, Frew A.
    J Allergy Clin Immunol; 2004 Oct 15; 114(4):831-7. PubMed ID: 15480323
    [Abstract] [Full Text] [Related]

  • 16. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial.
    Kleine-Tebbe J, Ribel M, Herold DA.
    Allergy; 2006 Feb 15; 61(2):181-4. PubMed ID: 16409193
    [Abstract] [Full Text] [Related]

  • 17. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study.
    Yukselen A, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB.
    Int Arch Allergy Immunol; 2012 Feb 15; 157(3):288-98. PubMed ID: 22041501
    [Abstract] [Full Text] [Related]

  • 18. High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study.
    Wahn U, Klimek L, Ploszczuk A, Adelt T, Sandner B, Trebas-Pietras E, Eberle P, Bufe A, SLIT Study Group.
    J Allergy Clin Immunol; 2012 Oct 15; 130(4):886-93.e5. PubMed ID: 22939758
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
    Rossi RE, Monasterolo G.
    Int Arch Allergy Immunol; 2004 Sep 15; 135(1):44-53. PubMed ID: 15286445
    [Abstract] [Full Text] [Related]

  • 20. Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis.
    Bowen T, Greenbaum J, Charbonneau Y, Hebert J, Filderman R, Sussman G, Del Carpio J, Gold M, Keith P, Moote W, Cecchetto S, Cecchetto O, Sharp D, Broutin O, André C.
    Ann Allergy Asthma Immunol; 2004 Nov 15; 93(5):425-30. PubMed ID: 15562880
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.